Nordisk Laboratories

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. The company is a dominant leader in the diabetes care market and has recently gained significant prominence for its leadership in the obesity treatment space with its GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy). Novo Nordisk's business is centered on serious chronic diseases, including rare blood disorders, endocrine disorders, and cardiovascular diseases. The company is well-known for its robust peptide-based drug discovery platform and its large-scale manufacturing capabilities for biologics. With a market capitalization that has made it one of the most valuable companies in Europe, Novo Nordisk continues to expand its pipeline into areas like MASH, heart failure, and chronic kidney disease.